Detail akcie CELON PHARMA online

Business Summary: Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Celon Pharma SA revenues decreased 20% to PLN180M. Net loss applicable to common stockholders totaled PLN54.2M vs. income of PLN33.5M. Revenues reflect Innovative-Foreign segment decrease of 95% to PLN3.2M, Generic Medicines-Foreign segment decrease of 5% to PLN35.2M. Net loss reflects Innovative segment loss totaling PLN55.3M vs. income of PLN8.8M.